Detection of the GH analog somatrogon in sports drug testing: Immunological approaches and LC-HRMS/MS.
LC‐HRMS/MS
affinity purification
doping
growth hormone analogue
tryptic digestion
Journal
Drug testing and analysis
ISSN: 1942-7611
Titre abrégé: Drug Test Anal
Pays: England
ID NLM: 101483449
Informations de publication
Date de publication:
11 Jul 2024
11 Jul 2024
Historique:
revised:
18
06
2024
received:
16
05
2024
accepted:
25
06
2024
medline:
12
7
2024
pubmed:
12
7
2024
entrez:
12
7
2024
Statut:
aheadofprint
Résumé
Due to the presumed lipolytic and anabolic properties, the misuse of human growth hormone (hGH) and its synthetic analogs in sports is prohibited both in- and out-of-competition. Within this research project, the detectability of somatrogon, a recombinant fusion glycoprotein of 22 kDa hGH and the C-terminal peptide (CTP) of the human chorionic gonadotropin (hCG) β-subunit, with current WADA-approved doping control assays for hGH and hCG was investigated. For that purpose, cross-reactivity tests and a somatrogon administration study were conducted, and only "Kit 2" of the GH isoform differential immunoassays proved applicable to the detection of somatrogon administration in serum. In urine, the immunoassay specific for total hCG yielded presumptively positive findings for several post-administration samples, which can probably be attributed to the presence of an immunoreactive fragment of the hCG β-subunit. As the detectability of somatrogon with these approaches was found to be limited, a highly specific detection assay (LOD: 10 ng/mL) for the drug in serum samples was developed by using affinity purification with GH receptor (GHR)-conjugated magnetic beads, proteolytic digestion, and liquid chromatography high-resolution tandem mass spectrometry (LC-HRMS/MS). Following optimization, the approach was comprehensively characterized, and authentic post-administration serum samples were successfully analyzed as proof-of-concept, indicating a detection window of at least 96 h. Consequently, the presented method can be employed to confirm the presence of somatrogon in serum samples, where only "Kit 2" of the currently used immunoassay kits yielded an abnormally high Rec/Pit ratio.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : US Anti-Doping Agency (USADA)
Organisme : Federal Ministry of the Interior, Building, and Community of the Federal Republic of Germany
Organisme : Manfred-Donike Institute for Doping Analysis
Informations de copyright
© 2024 The Author(s). Drug Testing and Analysis published by John Wiley & Sons Ltd.
Références
Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev. 2009;30(2):152‐177. doi:10.1210/er.2008‐0027
Kohler M, Thomas A, Püschel K, Schänzer W, Thevis M. Identification of human pituitary growth hormone variants by mass spectrometry. J Proteome Res. 2009;8(2):1071‐1076. doi:10.1021/pr800945b
Ranke MB, Wit JM. Growth hormone ‐ past, present and future. Nat Rev Endocrinol. 2018;14(5):285‐300. doi:10.1038/nrendo.2018.22
Holt RI, Sönksen PH. Growth hormone, IGF‐I and insulin and their abuse in sport. Br J Pharmacol. 2008;154(3):542‐556. doi:10.1038/bjp.2008.99
World Anti‐Doping Agency (WADA), World Anti‐Doping Code ‐ International Standard: Prohibited List 2024. Available at: www.wada-ama.org 2023.
Bidlingmaier M, Wu Z, Strasburger CJ. Problems with GH doping in sports. J Endocrinol Invest. 2003;26(9):924‐931. doi:10.1007/BF03345245
Holt RI. Detecting growth hormone abuse in athletes. Drug Test Anal. 2009;1(9‐10):426‐433. doi:10.1002/dta.59
Pfizer Inc., Pfizer Medical Information: Genotropin. Available at: https://www.pfizermedicalinformation.com/genotropin/
Wu Z, Bidlingmaier M, Dall R, Strasburger CJ. Detection of doping with human growth hormone. Lancet (London, England). 1999;353(9156):895. doi:10.1016/S0140‐6736(99)00775‐8
Bidlingmaier M, Wu Z, Strasburger CJ. Test method: GH. Bailliere's Best Practice & Research Clinical Endocrinology & Metabolism. 2000;14(1):99‐109. doi:10.1053/beem.2000.0057
Wallace JD, Cuneo RC, Bidlingmaier M, Lundberg PA, et al. Changes in non‐22‐kilodalton (kDa) isoforms of growth hormone (GH) after administration of 22‐kDa recombinant human GH in trained adult males. J Clin Endocrinol Metab. 2001;86(4):1731‐1737. doi:10.1210/jc.86.4.1731
Bidlingmaier M, Suhr J, Ernst A, et al. High‐sensitivity chemiluminescence immunoassays for detection of growth hormone doping in sports. Clin Chem. 2009;55(3):445‐453. doi:10.1373/clinchem.2008.112458
World Anti‐Doping Agency (WADA), WADA Technical Document TD2021GH: Human Growth Hormone (hGH) Isoform Differential Immunoassays for Doping Control Analysis. Available at: www.wada-ama.org 2020.
Hanley JA, Saarela O, Stephens DA, Thalabard JC. hGH isoform differential immunoassays applied to blood samples from athletes: decision limits for anti‐doping testing. Growth Horm IGF Res. 2014;24(5):205‐215. doi:10.1016/j.ghir.2014.06.001
World Anti‐Doping Agency (WADA), Laboratory Guidelines: Human Growth Hormone (hGH) Biomarkers Test (Version 3.0). Available at: www.wada-ama.org 2021.
World Anti‐Doping Agency (WADA), Summary of Major Modifications and Explanatory Notes: 2022 Prohibited List. Available at: www.wada-ama.org 2021.
Fares F, Guy R, Bar‐Ilan A, Felikman Y, Fima E. Designing a long‐acting human growth hormone (hGH) by fusing the carboxyl‐terminal peptide of human chorionic gonadotropin beta‐subunit to the coding sequence of hGH. Endocrinology. 2010;151(9):4410‐4417. doi:10.1210/en.2009‐1431
Lamb YN. Somatrogon: first approval. Drugs. 2022;82(2):227‐234. doi:10.1007/s40265‐021‐01663‐2
Fares, F., Fima, E., United States Patent Application Publication 2010.
European Medicines Agency (EMA). ‐ Committee for Medicinal Products for Human Use (CHMP), Assessment Report Ngenla 2021.
Hershkovitz, O., Moschcovich, L., in: (WIPO), W. I. P. P. (Ed.) 2016.
World Anti‐Doping Agency (WADA), WADA Technical Document – TD2021CG/LH: Analysis, Reporting & Management of Urinary Human Chorionic Gonadotrophin (hCG) and Luteinizing Hormone (LH) Findings in Male Athletes. Available at: www.wada-ama.org 2020.
National Library of Medicine (NLM), National Center for Biotechnology Information (NCBI), BLAST ® » blastp suite: Standard Protein BLAST. Available at: https://blast.ncbi.nlm.nih.gov/Blast.cgi?PAGE=Proteins
Walpurgis K, Thomas A, Vogel M, et al. Testing for the erythropoiesis‐stimulating agent Sotatercept/ACE‐011 (ActRIIA‐fc) in serum by means of Western blotting and LC‐HRMS. Drug Test Anal. 2016;8(11‐12):1152‐1161. doi:10.1002/dta.2093
Walpurgis K, Weigand T, Knoop A, et al. Detection of follistatin‐based inhibitors of the TGF‐β signaling pathways in serum/plasma by means of LC‐HRMS/MS and Western blotting. Drug Test Anal. 2020;12(11‐12):1636‐1648. doi:10.1002/dta.2925
Walpurgis K, Thomas A, Thevis M. Detection of the myostatin‐neutralizing antibody Domagrozumab in serum by means of Western blotting and LC‐HRMS. Drug Test Anal. 2019;11(11‐12):1714‐1723. doi:10.1002/dta.2729
Walpurgis K, Thomas A, Dellanna F, Schänzer W, Thevis M. Detection of the human anti‐ActRII antibody Bimagrumab in serum by means of affinity purification, tryptic digestion, and LC‐HRMS. Proteomics Clin Appl. 2018;12(3):e1700120. doi:10.1002/prca.201700120
World Anti‐Doping Agency (WADA), World Anti‐Doping Code ‐ International Standard: Laboratories. Available at: www.wada-ama.org 2021.
Australian Government ‐ Department of Health and Aged Care. : Therapeutic Goods Administration, Ngenla. Available at: https://www.tga.gov.au/resources/auspmd/ngenla 2021.
Clinical Trials Arena, Available at: https://www.clinicaltrialsarena.com/projects/ngenla-somatrogon-for-the-treatment-of-paediatric-growth-hormone-deficiency-usa/?cf-view 2024.
European Medicines Agency (EMA). ‐ Committee for Medicinal Products for Human Use (CHMP), Ngenla. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/ngenla 2022.
Zelinska N, Iotova V, Skorodok J, et al. Long‐acting C‐terminal peptide‐modified hGH (MOD‐4023): results of a safety and dose‐finding study in GHD children. J Clin Endocrinol Metab. 2017;102(5):1578‐1587. doi:10.1210/jc.2016‐3547
Deal CL, Steelman J, Vlachopapadopoulou E, et al. Efficacy and safety of weekly Somatrogon vs daily Somatropin in children with growth hormone deficiency: a phase 3 study. J Clin Endocrinol Metab. 2022;107(7):e2717‐e2728. doi:10.1210/clinem/dgac220
Hershkovitz O, Bar‐Ilan A, Guy R, et al. In vitro and in vivo characterization of MOD‐4023, a long‐acting Carboxy‐terminal peptide (CTP)‐modified human growth hormone. Mol Pharm. 2016;13(2):631‐639. doi:10.1021/acs.molpharmaceut.5b00868
University of Florida Health (UFHealth), Conditions and Treatments: Growth hormone test. Available at: https://ufhealth.org/conditions-and-treatments/growth-hormone-test